![[CCO] Certification Coaching Organization LLC](https://www.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Risk adjustment is the process of modifying capitation payments or insurance premiums to account for differences in the expected health costs of individuals based on their diagnoses and demographic factors. In obstetrics and gynecology (OBGYN), numerous conditions carry significant risk-adjustment weight across multiple payment models — including the HHS-HCC model used for ACA marketplace plans, the CMS-HCC v28 model used for Medicare Advantage, and the Chronic Illness and Disability Payment System (CDPS) used in Medicaid managed care.
OBGYN conditions that risk-adjust span two distinct clinical populations:
- Obstetric (pregnancy) complications — captured under the HHS-HCC Adult Female model, which includes a dedicated pregnancy-complication hierarchy. These diagnoses trigger prospective payment adjustments for exchange plans and affect premium calculation for childbearing-age enrollees.
- Gynecologic chronic conditions and malignancies — captured under CMS-HCC v28 for Medicare-age women (65+), where female-specific cancers (ovarian, cervical, endometrial, breast) map to high-weight HCC categories, and musculoskeletal conditions common in postmenopausal women (osteoporosis with fracture) carry meaningful coefficients.
Accurate, complete clinical documentation of these conditions is essential because each maps to a specific ICD-10-CM code that determines whether — and how much — the plan is compensated for the member’s expected resource utilization. Undercoding or vague documentation results in financial under-recovery; overcoding without clinical evidence creates audit and compliance risk.
📝 Coder Note
This CDG covers the full spectrum of OBGYN risk-adjusting conditions across three models: HHS-HCC (ACA exchanges), CMS-HCC v28 (Medicare Advantage), and CDPS (Medicaid). Each model has different hierarchies, coefficient weights, and data submission windows. Know which payer model applies before abstracting.
🗂️ Alternative Terminology
| Formal / ICD-10 Term | Colloquial / Lay Names & Synonyms |
|---|---|
| Ectopic pregnancy | Tubal pregnancy, fallopian tube pregnancy |
| Complete molar pregnancy | Hydatidiform mole (complete), molar gestation |
| Severe pre-eclampsia | Severe toxemia of pregnancy, severe gestational hypertension with proteinuria |
| Eclampsia | Pregnancy seizures, convulsions in pregnancy |
| HELLP syndrome | Hemolysis, elevated liver enzymes, low platelets — a severe preeclampsia variant |
| Gestational diabetes mellitus (GDM) | Diabetes during pregnancy, pregnancy diabetes, glucose intolerance of pregnancy |
| Abruptio placentae | Placental abruption, premature placental separation |
| Placenta previa | Low-lying placenta, placenta over the cervix |
| Antepartum hemorrhage | Bleeding in pregnancy, obstetric hemorrhage |
| Amniotic fluid disorders | Polyhydramnios, oligohydramnios, low fluid, too much fluid |
| Preterm labor | Premature labor, early labor, labor before 37 weeks |
| Cervical insufficiency | Incompetent cervix, cervical weakness, short cervix |
| Multiple gestation | Twins, triplets, higher-order multiples |
| Pregnancy-related VTE | DVT in pregnancy, pulmonary embolism in pregnancy, blood clot in pregnancy |
| Ovarian cancer | Ovarian carcinoma, ovarian malignancy |
| Cervical cancer | Cancer of the cervix uteri, cervical carcinoma |
| Endometrial cancer | Uterine cancer, cancer of the uterine body, endometrial carcinoma |
| Leiomyosarcoma of uterus | Uterine sarcoma, malignant uterine fibroid |
| Osteoporosis with pathological fracture | Brittle bone fracture, fragility fracture, osteoporotic fracture |
| BRCA1/BRCA2 genetic susceptibility | BRCA mutation, hereditary breast-ovarian cancer gene |
🩺 Signs & Symptoms
Clinical presentations vary considerably across the OBGYN risk-adjusting spectrum. Coders and CDI specialists should recognize these presentations as triggers for further specificity queries.
Obstetric Complications
- Severe preeclampsia/eclampsia: Severe hypertension (≥160/110 mmHg), new proteinuria, headache, visual disturbances, RUQ or epigastric pain, pulmonary edema, thrombocytopenia, seizures (eclampsia)
- HELLP syndrome: Epigastric or RUQ pain, nausea/vomiting, malaise, laboratory findings of hemolysis (elevated LDH, low haptoglobin), elevated AST/ALT, platelet count <100,000/µL
- Abruptio placentae: Painful vaginal bleeding, uterine rigidity or “woody” feel, fetal heart rate abnormalities, back pain
- Placenta previa: Painless bright-red vaginal bleeding, typically after 20 weeks
- Ectopic/molar pregnancy: Unilateral pelvic pain, vaginal bleeding, nausea, markedly elevated or abnormal β-hCG levels, absent intrauterine pregnancy on ultrasound
- Pregnancy-related VTE: Unilateral leg swelling, calf tenderness, dyspnea, pleuritic chest pain, tachycardia, hypoxia
Gynecologic Malignancies (Medicare population)
- Ovarian cancer: Bloating, pelvic/abdominal pain, early satiety, urinary urgency, unintentional weight loss; often late-stage at diagnosis
- Cervical cancer: Abnormal vaginal bleeding (post-coital, between periods, post-menopausal), pelvic pain, vaginal discharge
- Endometrial cancer: Post-menopausal uterine bleeding (most common presenting symptom), pelvic pain, watery/bloody vaginal discharge
Postmenopausal Conditions
- Osteoporosis with fracture: Acute pain at fracture site, height loss, kyphosis, vertebral compression pain, fragility fractures from low-energy trauma (hip, vertebral, distal radius)
🧭 Differential Diagnosis
| Condition | Key Differential Diagnoses | Distinguishing Features |
|---|---|---|
| Severe preeclampsia | Chronic hypertension; gestational hypertension; HELLP syndrome; acute fatty liver of pregnancy | Onset after 20 weeks + proteinuria + severe BP; HELLP confirmed by labs; eclampsia = seizures present |
| Abruptio placentae | Placenta previa; uterine rupture; bloody show; vasa previa | Painful vs. painless bleeding; rigid uterus vs. soft; ultrasound findings |
| Ectopic pregnancy | Threatened/inevitable abortion; appendicitis; ovarian cyst rupture; PID | Absent IUP on transvaginal U/S; β-hCG pattern; unilateral adnexal mass |
| Pregnancy-related VTE | Muscle strain; cellulitis; pulmonary embolism vs. pneumonia; amniotic fluid embolism | Duplex ultrasound for DVT; CT-PA or V/Q scan for PE; elevated D-dimer (not reliable in pregnancy) |
| Ovarian cancer | Ovarian cyst; endometriosis; fibroid; colorectal cancer; diverticulitis | CA-125; CT/MRI imaging; biopsy for histology; age/BRCA risk |
| Endometrial cancer | Endometrial hyperplasia; cervical polyp; atrophic vaginitis; cervical cancer | Endometrial biopsy; histological confirmation; curettage/hysteroscopy |
| Osteoporosis with fracture | Metastatic bone disease; multiple myeloma; Paget’s disease; traumatic fracture | DEXA scan T-score; fracture from minimal trauma; bone survey; SPEP/labs |
| Gestational diabetes | Pre-existing type 1 or type 2 DM; impaired glucose tolerance pre-pregnancy | Onset in pregnancy; OGTT results; resolution post-partum for true GDM |
📋 Clinical Indicators for Coders/CDI
| Condition | Clinical Indicators Requiring Capture | Documentation Gap Risk |
|---|---|---|
| Severe preeclampsia / Eclampsia / HELLP | BP ≥160/110 on two occasions, proteinuria, lab evidence (LDH, AST/ALT, platelets), seizures, antihypertensive therapy ordered for severe range BP | HIGH — Often documented as “preeclampsia” without specifying severe features; HELLP requires specific lab-based documentation |
| Gestational diabetes | Abnormal OGTT (50g screen + 100g diagnostic); insulin or glyburide prescribed; dietary management initiated; glucose logs in record | MODERATE — Distinguish GDM from pre-existing DM complicating pregnancy (O24.0xx–O24.3xx vs. O24.4xx) |
| Abruptio placentae | Painful bleeding, retroplacental clot on ultrasound, Kleihauer-Betke test, fetal distress, emergency C/S for abruption | HIGH — Type (with/without hemorrhage) and trimester specificity needed |
| Placenta previa | Low-lying or previa on ultrasound, hemorrhage documentation, delivery method (C/S), maternal blood loss quantification | HIGH — Must specify with/without hemorrhage; O44.0x vs. O44.1x, etc. |
| Pregnancy-related VTE | Duplex U/S or CT-PA confirming DVT/PE in pregnancy, anticoagulation initiated (heparin, LMWH), IVC filter placed | HIGH — Site specificity (superficial/deep), laterality, antepartum vs. postpartum |
| Cervical insufficiency | Cervical length <25mm on ultrasound, cervical cerclage placed, bedrest or progesterone prescribed for short cervix | MODERATE — Must differentiate cerclage history vs. current insufficiency |
| Multiple gestation | Chorionicity/amnionicity documented on ultrasound, number of fetuses, fetal complications | MODERATE — Monoamniotic, dichorionic details affect code specificity |
| Ovarian/cervical/endometrial cancer | Pathology report with histologic type, stage documented (TNM or FIGO), current treatment (chemo, radiation, surgery) | HIGH — Primary vs. metastatic affects HCC hierarchy (HCC 10 vs. HCC 17 vs. HCC 22) |
| Osteoporosis with fracture | DEXA T-score ≤-2.5, pathological fracture confirmed, fracture site documented, cause (low-energy trauma), bisphosphonate use | HIGH — Osteoporosis without fracture ≠ HCC; M80.x (with fracture) → HCC 170-171 |
⚠️ Common Pitfall
Osteoporosis without fracture (M81.x) does NOT map to any HCC in CMS-HCC v28 and carries no RAF weight. Only osteoporosis with current pathological fracture (M80.xx) maps to HCC 170 (Pathological Fracture Not Due to Neoplasm or Osteoporosis) or HCC 171. Coders must query for fracture presence and site when the record shows severe osteoporosis with fall or acute pain.
🦴 Anatomy & Pathophysiology
Obstetric Physiology and Risk Adjustment Rationale
The HHS-HCC risk adjustment model for ACA exchange plans uses a concurrent model — diagnoses from the current benefit year predict that year’s expenditures. The model includes a dedicated Adult Female age-sex rating category and incorporates pregnancy hierarchy groups specifically because obstetric complications dramatically increase medical expenditures within a plan year. The payment transfer ensures plans that enroll high-risk pregnancies are compensated, preventing adverse selection.
Physiologically, many pregnancy complications share a common pathophysiologic thread of placental dysfunction and uteroplacental insufficiency:
- Preeclampsia/HELLP/eclampsia: Abnormal placentation leads to endothelial dysfunction, systemic vasoconstriction, multi-organ involvement. The ACOG Hypertension in Pregnancy guidelines distinguish gestational hypertension, preeclampsia without severe features, severe features, and eclampsia — each maps to a distinct ICD-10-CM category.
- Abruptio placentae: Premature separation of the normally implanted placenta from the uterine wall, leading to fetal hypoxia, maternal hemorrhage, and DIC in severe cases.
- Placenta previa: Abnormal placentation overlying or adjacent to the internal cervical os; vascular disruption causes hemorrhage, especially with cervical effacement.
- Gestational diabetes: Placental hormones (human placental lactogen, progesterone) induce progressive insulin resistance. Maternal pancreatic beta cell failure to compensate causes hyperglycemia. Risk of macrosomia, neonatal hypoglycemia, operative delivery.
- Pregnancy-related VTE: Virchow’s triad (hypercoagulability, venous stasis, endothelial injury) is amplified in pregnancy by elevated clotting factors, uterine compression of iliac veins, and prolonged immobility. DVT risk is 5× higher in pregnancy; PE is a leading cause of maternal mortality.
Gynecologic Malignancies
Ovarian cancer (C56.x) arises most commonly from the epithelium of the ovarian surface or fallopian tube. High-grade serous carcinoma accounts for ~70% of cases. Late-stage diagnosis is common due to non-specific early symptoms. BRCA1/BRCA2 mutations (Z15.01, Z15.02) confer 40–50% lifetime risk for ovarian cancer and up to 72% for breast cancer, per NCI data.
Cervical cancer (C53.x) is caused in nearly all cases by persistent high-risk HPV infection. Squamous cell carcinoma is most common. The ASCCP manages cervical cancer screening guidelines.
Endometrial cancer (C54.x) is the most common gynecologic malignancy in the U.S. Type I (endometrioid, estrogen-driven) accounts for ~80% of cases; Type II (serous, clear cell) is more aggressive. Postmenopausal bleeding is the cardinal symptom enabling early detection.
Osteoporosis with fracture in postmenopausal women results from estrogen deficiency after menopause, accelerating bone resorption. The NIH Osteoporosis overview notes that one in two women over 50 will have an osteoporosis-related fracture. Hip fractures carry 20–30% one-year mortality in elderly women.
💊 Medication Impact / Treatment
Obstetric Risk-Adjusting Conditions
- Preeclampsia/Eclampsia/HELLP: Magnesium sulfate (seizure prophylaxis/treatment), antihypertensives (labetalol IV, hydralazine IV, nifedipine PO for acute severe BP), corticosteroids (betamethasone for fetal lung maturity if preterm), delivery as definitive treatment
- Gestational diabetes: Medical nutrition therapy (MNT) first-line; insulin (preferred in pregnancy — rapid-acting aspart, lispro; NPH); glyburide (limited use); metformin (off-label, crosses placenta). ACOG Practice Bulletin on GDM governs clinical management.
- Preterm labor: Tocolytics (nifedipine, indomethacin); 17-alpha hydroxyprogesterone caproate (17-OHPC/J1725) — Note: Makena (brand 17-OHPC) was withdrawn from the U.S. market by FDA in 2023; compounded 17-OHPC may still be prescribed. Progesterone vaginal suppositories (Endometrin) for short cervix/cerclage patients.
- Cervical insufficiency: Cervical cerclage (surgical); vaginal progesterone (Prometrium/Endometrin); bedrest/activity restriction
- Pregnancy-related VTE: Unfractionated heparin or low molecular weight heparin (LMWH, enoxaparin/Lovenox) — anticoagulants of choice in pregnancy (do not cross placenta). Warfarin contraindicated in first trimester. DOACs contraindicated in pregnancy.
- Medroxyprogesterone depot (J1050 — Depo-Provera): Injectable contraceptive; also used for endometriosis-related pain management. Not a risk-adjustment trigger itself but relevant to CDI context.
Gynecologic Malignancies and Postmenopausal Conditions
- Ovarian cancer: Surgical debulking (cytoreductive surgery); platinum-based chemotherapy (carboplatin + paclitaxel); PARP inhibitors (olaparib, niraparib) for BRCA-mutated disease; bevacizumab in advanced disease
- Cervical cancer: Radical hysterectomy (early stage); concurrent cisplatin-based chemoradiation (locally advanced); immune checkpoint inhibitors (pembrolizumab) for recurrent/metastatic PD-L1+ disease per NCCN guidelines
- Endometrial cancer: Total hysterectomy with bilateral salpingo-oophorectomy (TH/BSO) ± lymph node dissection; progestin therapy (megestrol acetate) for early-stage/fertility-sparing; pembrolizumab + lenvatinib for advanced/recurrent
- Osteoporosis with fracture: Bisphosphonates (alendronate, risedronate, zoledronic acid IV); denosumab (Prolia); teriparatide/abaloparatide (anabolic); calcium + vitamin D supplementation; fall prevention programs
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines (FY2026)
OB Coding — Chapter 15 (O00–O9A)
Per the FY2026 ICD-10-CM Official Guidelines, Chapter 15:
- 7th character requirement: Most obstetric codes require a 7th character indicating the trimester (1=first, 2=second, 3=third) or fetus identifier for multiple gestations (0=not applicable/single, 1=fetus 1, 2=fetus 2, etc.). Failure to use the correct 7th character results in an invalid code.
- Principal diagnosis for delivery episode: When a delivery occurs, the principal diagnosis should be the condition that prompted admission or, if present, the delivery code itself. Complications that developed during admission should be coded as additional diagnoses.
- Preeclampsia hierarchy: Guideline I.C.15.b — When severe features are present, use the severe preeclampsia codes (O14.1x, O14.2x HELLP). Do NOT code preeclampsia without severe features (O14.0x) if severe features are documented. Eclampsia (O15.xx) is coded instead of preeclampsia when seizures occur.
- Gestational diabetes: Guideline I.C.15.g — GDM (O24.4xx) is diabetes arising in pregnancy. Distinguish from pre-existing DM (O24.0x–O24.3x). The 6th character specifies diet-controlled (0), insulin-controlled (1), controlled by oral medication (2), or unspecified (9).
- Multiple gestation complications: For complications affecting a specific fetus in multiple gestation, the 7th character (1–9) identifies which fetus is affected. Code O30.x for the multiple gestation itself.
- Postpartum vs. antepartum: Conditions occurring before delivery are antepartum; those occurring after are postpartum. VTE codes (O22.x antepartum; O87.x postpartum) differ accordingly.
- Cervical insufficiency/cerclage: O34.3x covers maternal care for cervical incompetence. If cerclage was placed in a prior pregnancy and patient has a current pregnancy with history of, code only if cerclage still in place or affecting current management.
GYN Coding — Chapter 2 (Neoplasms) and Chapter 13 (Musculoskeletal)
- Cancer coding guideline I.C.2: Code the current malignancy as primary vs. metastatic. Ovarian cancer with peritoneal metastasis — code the ovarian primary (C56.x) as principal if treating the primary; code metastatic peritoneum (C78.6) as additional. If only treating metastasis, the metastatic site may be principal.
- BRCA susceptibility (Z15.01, Z15.02): These Z codes are NOT diagnoses of cancer — they indicate genetic susceptibility. Per Guideline I.C.21.c.6, if the patient currently has the associated condition (e.g., breast cancer), code the cancer first and Z15.0x as additional. If no current malignancy, Z15.0x may be coded as reason for encounter (screening, counseling).
- Osteoporosis with fracture (M80.x): Per Guideline I.C.13.d, age-related (postmenopausal) osteoporosis is M81.0; when a fragility fracture is present, use M80.0xx (or M80.8xx with 5th/6th character for site). The fracture must be documented as due to osteoporosis (fragility/pathological from low-energy trauma), not traumatic.
- Sequencing: For encounters primarily for chemotherapy/radiation of gynecologic malignancies, the Z code for encounter type (Z51.11 encounter for antineoplastic chemotherapy; Z51.0 for radiotherapy) may be principal per Guideline I.C.2.e, with the malignancy as additional.
🛡️ Audit Alert
For obstetric HHS-HCC risk adjustment, diagnosis data must be submitted on claims during the benefit year. Risk adjustment for ACA plans uses encounter data (all-payer claims data or EDGE server submissions). All pregnancy complication codes must appear on professional or facility claims from encounters within the benefit year — not just on the delivery claim. Ensure antenatal visit claims capture severity-specific codes (e.g., O14.12 Severe preeclampsia in second trimester) at each prenatal encounter where the condition is addressed.
🔢 ICD-10-CM Code Set (FY2026)
Pregnancy Complications — HHS-HCC Risk-Adjusting Codes
| ICD-10-CM Code | Description | Notes / HHS-HCC Category |
|---|---|---|
| O01.0 | Classical hydatidiform mole (complete) | HHS-HCC Pregnancy Complications. Requires histologic confirmation. Follow-up β-hCG monitoring required. |
| O01.1 | Incomplete and partial hydatidiform mole | HHS-HCC. Partial mole may have fetal tissue; distinct from complete mole. |
| O01.9 | Hydatidiform mole, unspecified | Use only when type cannot be confirmed from documentation. |
| O00.00 | Abdominal pregnancy without intrauterine pregnancy | HHS-HCC Ectopic/Molar Pregnancy category. Very rare; high mortality risk. |
| O00.01 | Abdominal pregnancy with intrauterine pregnancy | Heterotopic pregnancy; extremely rare. |
| O00.10 | Tubal pregnancy without intrauterine pregnancy | HHS-HCC. Most common site (~95%) for ectopic pregnancy. |
| O00.11 | Tubal pregnancy with intrauterine pregnancy | Heterotopic; monitor IUP closely after ectopic management. |
| O00.20 | Ovarian pregnancy without intrauterine pregnancy | HHS-HCC Ectopic category. |
| O00.211 | Right ovarian pregnancy without intrauterine pregnancy | FY2026 laterality specificity. |
| O00.212 | Left ovarian pregnancy without intrauterine pregnancy | FY2026 laterality specificity. |
| O14.10 | Severe pre-eclampsia, unspecified trimester | HHS-HCC Severe Preeclampsia/Eclampsia. Use only if trimester not documented. |
| O14.12 | Severe pre-eclampsia, second trimester | HHS-HCC. Document BP ≥160/110 + proteinuria + severe features. |
| O14.13 | Severe pre-eclampsia, third trimester | HHS-HCC. Most common trimester for severe PE. Specify antepartum. |
| O14.14 | Severe pre-eclampsia, complicating childbirth | HHS-HCC. Present at time of delivery. |
| O14.15 | Severe pre-eclampsia, complicating the puerperium | HHS-HCC. Up to 6 weeks postpartum. |
| O14.20 | HELLP syndrome, unspecified trimester | HHS-HCC. Labs required: hemolysis (LDH >600 U/L), AST/ALT >70, platelets <100K. |
| O14.22 | HELLP syndrome, second trimester | HHS-HCC. |
| O14.23 | HELLP syndrome, third trimester | HHS-HCC. Most common timing. |
| O14.24 | HELLP syndrome, complicating childbirth | HHS-HCC. |
| O14.25 | HELLP syndrome, complicating the puerperium | HHS-HCC. |
| O15.00 | Eclampsia in pregnancy, unspecified trimester | HHS-HCC Eclampsia. Seizures in pregnancy without prior history of seizure disorder. |
| O15.02 | Eclampsia in pregnancy, second trimester | HHS-HCC. |
| O15.03 | Eclampsia in pregnancy, third trimester | HHS-HCC. |
| O15.1 | Eclampsia in labor | HHS-HCC. |
| O15.2 | Eclampsia in the puerperium | HHS-HCC. Postpartum eclampsia can occur up to 4–6 weeks after delivery. |
| O24.410 | Gestational diabetes mellitus in pregnancy, diet controlled | HHS-HCC (may apply). 6th character 0=diet, 1=insulin, 2=oral meds, 9=unspecified. |
| O24.414 | Gestational diabetes mellitus in pregnancy, insulin controlled | HHS-HCC. Higher resource utilization; code insulin use. |
| O24.415 | Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs | HHS-HCC (may apply). Glyburide or metformin. |
| O24.419 | Gestational diabetes mellitus in pregnancy, unspecified control | Query for specificity — diet vs. insulin vs. oral medication. |
| O45.001 | Premature separation of placenta with coagulation defect, unspecified, first trimester | HHS-HCC Abruptio Placentae. Specify trimester and type (with/without coagulation defect, with/without hemorrhage). |
| O45.8X1 | Other premature separation of placenta, first trimester | HHS-HCC. |
| O45.8X2 | Other premature separation of placenta, second trimester | HHS-HCC. |
| O45.8X3 | Other premature separation of placenta, third trimester | HHS-HCC. Most common trimester for abruption. |
| O44.00 | Placenta previa specified as without hemorrhage, unspecified trimester | HHS-HCC Placenta Previa. FY2026 — specify with or without hemorrhage; trimester. |
| O44.10 | Placenta previa with hemorrhage, unspecified trimester | HHS-HCC. Active bleeding increases severity and resource use. |
| O44.21 | Partial placenta previa without hemorrhage, first trimester | HHS-HCC. |
| O44.31 | Partial placenta previa with hemorrhage, first trimester | HHS-HCC. |
| O44.40 | Low lying placenta NOS or without hemorrhage, unspecified trimester | Low-lying placenta that does not reach the cervical os; still risk-adjusting when hemorrhage present. |
| O44.53 | Low lying placenta with hemorrhage, third trimester | HHS-HCC. |
| O46.001 | Antepartum hemorrhage with coagulation defect, unspecified, first trimester | HHS-HCC Antepartum Hemorrhage. Must document source and trimester. |
| O46.8X1 | Other antepartum hemorrhage, first trimester | HHS-HCC. |
| O46.8X3 | Other antepartum hemorrhage, third trimester | HHS-HCC. |
| O40.1XX0 | Polyhydramnios, first trimester, not applicable or unspecified | HHS-HCC Amniotic Fluid Disorders. 7th character required for multiple gestation fetus ID. |
| O40.2XX0 | Polyhydramnios, second trimester, fetus unspecified | HHS-HCC. |
| O40.3XX0 | Polyhydramnios, third trimester, fetus unspecified | HHS-HCC. AFI >24 cm or deepest pocket >8 cm. |
| O41.00X0 | Oligohydramnios, unspecified trimester, fetus unspecified | HHS-HCC. AFI <5 cm. Associated with renal agenesis, IUGR, post-dates. |
| O41.01X0 | Oligohydramnios, first trimester | HHS-HCC. |
| O41.02X0 | Oligohydramnios, second trimester | HHS-HCC. |
| O41.03X0 | Oligohydramnios, third trimester | HHS-HCC. |
| O60.00 | Preterm labor without delivery, unspecified trimester | HHS-HCC. See Preterm Labor CDG. |
| O60.12X0 | Preterm labor second trimester with preterm delivery second trimester | HHS-HCC. Must document whether delivery occurred and at what gestational age. |
| O60.13X0 | Preterm labor second trimester with preterm delivery third trimester | HHS-HCC. |
| O60.14X0 | Preterm labor third trimester with preterm delivery third trimester | HHS-HCC. |
| O34.30 | Maternal care for cervical incompetence, unspecified trimester | HHS-HCC Cervical Insufficiency. Specify trimester; note if cerclage in place. |
| O34.31 | Maternal care for cervical incompetence, first trimester | HHS-HCC. |
| O34.32 | Maternal care for cervical incompetence, second trimester | HHS-HCC. Most common trimester for cerclage placement. |
| O34.33 | Maternal care for cervical incompetence, third trimester | HHS-HCC. |
| O30.001 | Twin pregnancy, unspecified number of placenta and amnion, first trimester | HHS-HCC Multiple Gestation. See Multiple Gestation CDG. Specify chorionicity/amnionicity when documented. |
| O30.011 | Twin pregnancy, monochorionic/monoamniotic, first trimester | HHS-HCC. Highest risk multiple gestation (TTTS, cord entanglement risk). |
| O30.031 | Twin pregnancy, dichorionic/diamniotic, first trimester | HHS-HCC. Most common type of twins. |
| O30.101 | Triplet pregnancy, unspecified number of placenta, first trimester | HHS-HCC Higher-Order Multiple Gestation. |
| O22.30 | Deep phlebothrombosis in pregnancy, unspecified trimester | HHS-HCC Pregnancy-Related VTE. Specify antepartum/postpartum, site, laterality. |
| O22.31 | Deep phlebothrombosis in pregnancy, first trimester | HHS-HCC. |
| O22.32 | Deep phlebothrombosis in pregnancy, second trimester | HHS-HCC. |
| O22.33 | Deep phlebothrombosis in pregnancy, third trimester | HHS-HCC. DVT risk highest in third trimester and peripartum. |
| O22.40 | Phlebothrombosis of deep veins of pelvis in pregnancy, unspecified trimester | HHS-HCC. Pelvic DVT may not manifest with typical leg symptoms. |
| O22.50 | Cerebral venous thrombosis in pregnancy, unspecified trimester | HHS-HCC. CVT in pregnancy — severe; presents with headache, focal neuro deficits, seizures. |
| O22.51 | Cerebral venous thrombosis in pregnancy, first trimester | HHS-HCC. |
| O22.52 | Cerebral venous thrombosis in pregnancy, second trimester | HHS-HCC. |
| O22.53 | Cerebral venous thrombosis in pregnancy, third trimester | HHS-HCC. |
Gynecologic Malignancies — CMS-HCC v28 Risk-Adjusting Codes
| ICD-10-CM Code | Description | HCC v28 Mapping / Notes |
|---|---|---|
| C56.1 | Malignant neoplasm of right ovary | CMS-HCC v28: HCC 17 (Metastatic Cancer and Acute Leukemia) if metastatic; HCC 22 (Lung and Other Severe Cancers) for localized. Specify laterality. |
| C56.2 | Malignant neoplasm of left ovary | CMS-HCC v28: HCC 17 or HCC 22 per staging. |
| C56.3 | Malignant neoplasm of bilateral ovaries | CMS-HCC v28: HCC 17 or HCC 22. FY2026 code for bilateral involvement. |
| C56.9 | Malignant neoplasm of unspecified ovary | Use only if laterality not determinable from documentation. |
| C53.0 | Malignant neoplasm of endocervix | CMS-HCC v28: HCC 22. Specify endocervix vs. exocervix. |
| C53.1 | Malignant neoplasm of exocervix | CMS-HCC v28: HCC 22. |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri | CMS-HCC v28: HCC 22. Use when tumor crosses endocervix/exocervix boundary. |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified | CMS-HCC v28: HCC 22. Query pathology for specificity. |
| C54.1 | Malignant neoplasm of endometrium | CMS-HCC v28: HCC 22. Most common subsite; specify endometrioid vs. serous histology if documented. |
| C54.2 | Malignant neoplasm of myometrium | CMS-HCC v28: HCC 22. |
| C54.3 | Malignant neoplasm of fundus uteri | CMS-HCC v28: HCC 22. |
| C54.8 | Malignant neoplasm of overlapping sites of corpus uteri | CMS-HCC v28: HCC 22. |
| C54.9 | Malignant neoplasm of corpus uteri, unspecified | CMS-HCC v28: HCC 22. |
| C55 | Malignant neoplasm of uterus, part unspecified | CMS-HCC v28: HCC 22. Includes leiomyosarcoma (uterine sarcoma) when site unspecified. Query for histology — sarcoma vs. carcinoma changes prognosis/treatment significantly. |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast | CMS-HCC v28: HCC 22. Breast cancer maps to HCC 22 (not HCC 17 unless metastatic). Specify laterality and quadrant/subsite. |
| C50.111 | Malignant neoplasm of central portion of right female breast | CMS-HCC v28: HCC 22. |
| C50.911 | Malignant neoplasm of unspecified site of right female breast | CMS-HCC v28: HCC 22. Query for site specificity within breast. |
| C50.912 | Malignant neoplasm of unspecified site of left female breast | CMS-HCC v28: HCC 22. |
| C78.6 | Secondary malignant neoplasm of retroperitoneum and peritoneum | CMS-HCC v28: HCC 17 (Metastatic Cancer). Common metastatic site for ovarian cancer. When coded with C56.x, sequencing depends on encounter reason. |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct | CMS-HCC v28: HCC 17. Hepatic metastasis from gynecologic primaries. |
| C79.60 | Secondary malignant neoplasm of unspecified ovary | CMS-HCC v28: HCC 17. Ovarian metastasis from other primary (Krukenberg tumor). |
| Z15.01 | Genetic susceptibility to malignant neoplasm of breast (BRCA1) | NOT an HCC — Z codes do not carry RAF weight. Code as additional for encounters addressing BRCA status, genetic counseling, enhanced surveillance. Triggers preventive service coding. |
| Z15.02 | Genetic susceptibility to malignant neoplasm of ovary (BRCA2) | NOT an HCC. Per CMS ICD-10-CM resources, Z codes generally do not map to HCC categories. |
Osteoporosis with Fracture — CMS-HCC v28
| ICD-10-CM Code | Description | HCC v28 / Notes |
|---|---|---|
| M80.00XA | Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter | CMS-HCC v28: HCC 170 (Hip Fracture/Pathological Fracture) or HCC 171. 7th character A=initial, D=subsequent, S=sequela. Use A for active treatment, D for follow-up. |
| M80.011A | Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter | CMS-HCC v28: HCC 170 or 171. Specify site and laterality. |
| M80.021A | Age-related osteoporosis with current pathological fracture, right humerus, initial encounter | CMS-HCC v28: HCC 170. |
| M80.051A | Age-related osteoporosis with current pathological fracture, right femur, initial encounter | CMS-HCC v28: HCC 170. Hip/femur fractures carry highest mortality burden and RAF weight in elderly women. |
| M80.052A | Age-related osteoporosis with current pathological fracture, left femur, initial encounter | CMS-HCC v28: HCC 170. |
| M80.061A | Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter | CMS-HCC v28: HCC 170. |
| M80.071A | Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter | CMS-HCC v28: HCC 170. |
| M80.08XA | Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter | CMS-HCC v28: HCC 170. Vertebral compression fractures are the most common osteoporotic fracture; often underdiagnosed. |
| M80.80XA | Other osteoporosis with current pathological fracture, unspecified site, initial encounter | CMS-HCC v28: HCC 170. Use for non-age-related osteoporosis (glucocorticoid-induced, disuse, etc.). |
| M81.0 | Age-related osteoporosis without current pathological fracture | NO HCC mapping in CMS-HCC v28. No RAF weight. Important distinction from M80.x. |
Non-Risk-Adjusting GYN Conditions (for context)
| Condition | ICD-10-CM | Risk Adjustment Status |
|---|---|---|
| Endometriosis | N80.0–N80.9 | No HCC mapping. Chronic, high-cost condition but not currently risk-adjusting under HHS-HCC or CMS-HCC v28. |
| Uterine leiomyoma (fibroids) | D25.0–D25.9 | No HCC. Benign neoplasm; does not risk-adjust. Leiomyosarcoma (C55) DOES map to HCC 22. |
| Chronic pelvic pain | N94.10–N94.19 | No HCC. Symptom code; underlying cause should be coded if established. |
| Pelvic organ prolapse | N81.0–N81.9 | No HCC. High surgical volume but no RAF impact. |
| Urinary incontinence | N39.3, N39.41–N39.498 | No HCC. Stress, urge, mixed incontinence — significant quality-of-life burden but no risk-adjustment weight. |
| Menopausal and postmenopausal disorders | N95.0–N95.9 | No HCC. Vasomotor symptoms, atrophic vaginitis — not risk-adjusting. |
| Ovarian cyst | N83.0–N83.29 | No HCC. Must be distinguished from ovarian malignancy — query pathology if cyst resected. |
💬 CDI Query Trigger
When a patient has a history of uterine fibroids AND a new uterine mass documented on imaging or pathology report as “high-grade spindle cell neoplasm” or “smooth muscle tumor of uncertain malignant potential (STUMP),” query the treating physician to clarify whether the diagnosis is a benign leiomyoma (D25.x), a leiomyosarcoma (C55), or STUMP (D39.0 — neoplasm of uncertain behavior). This distinction has significant HCC and treatment implications.
🔎 Indexing
The FY2026 ICD-10-CM Alphabetic Index provides the following lead terms for key conditions:
- Preeclampsia → Pre-eclampsia → with pre-existing hypertension O11.x; severe features O14.1x; HELLP O14.2x; superimposed O11.x
- Eclampsia → Eclampsia, eclamptic → complicating pregnancy, childbirth, puerperium O15.x
- Diabetes, gestational → Diabetes, diabetic → gestational O24.4x. Do NOT index under “Diabetes mellitus” for GDM.
- Abruptio placentae → Abruptio placentae → with hemorrhage, without hemorrhage, with coagulation defect O45.xx
- Placenta previa → Placenta, placental → previa → complete, partial, marginal; with/without hemorrhage O44.xx
- Ectopic pregnancy → Pregnancy, ectopic → with intrauterine pregnancy; by site (tubal, ovarian, abdominal, etc.) O00.xx
- Hydatidiform mole → Mole, hydatidiform → classical (complete) O01.0; incomplete/partial O01.1
- Thrombosis, venous, in pregnancy → Phlebothrombosis → antepartum O22.x; postpartum O87.x
- Cancer, malignant neoplasm of ovary → Neoplasm Table → Ovary → Malignant Primary C56.x; Secondary C79.6x
- Osteoporosis, with fracture → Osteoporosis → age-related, with current pathological fracture M80.0xx; other M80.8xx. Without fracture → M81.x (no fracture extension)
- BRCA → Susceptibility → genetic → malignant neoplasm → breast (BRCA1) Z15.01; ovary (BRCA2) Z15.02
📝 Coder Note
When indexing osteoporosis with fracture, the Alphabetic Index instructs coders to use additional code for associated major osseous defect (M89.7x) when applicable. A common indexing error is coding M81.0 (without fracture) when the chart clearly documents a fracture — always verify whether a current pathological fracture is documented before selecting the M81 series.
🏥 CPT (2026)
Obstetric Global Package and Antepartum Services
| CPT Code | Description | Global Period | Notes |
|---|---|---|---|
| 59400 | Routine obstetric care including antepartum care, vaginal delivery and postpartum care | Global OB package | Includes all antepartum visits, delivery, and 6-week postpartum visit. Complications billed separately with modifier 22 or unbundled CPT for the complication. |
| 59510 | Routine obstetric care including antepartum care, cesarean delivery and postpartum care | Global OB package | Use when C/S is planned. If C/S is unplanned (emergency), may use 59618+59622 or modifier for change in delivery method. |
| 59514 | Cesarean delivery only | 000 days | For emergent C/S not preceded by antepartum care by same provider. |
| 59515 | Cesarean delivery including postpartum care | Global | |
| 59618 | Routine obstetric care including antepartum care, cesarean delivery following attempted vaginal delivery after previous cesarean delivery, and postpartum care | Global | TOLAC/VBAC-related C/S code. |
| 59025 | Fetal non-stress test (NST) | 000 | Billed separately for high-risk OB monitoring for preeclampsia, GDM, IUGR, postdates, multiple gestation. |
| 59020 | Fetal contraction stress test (OCT) | 000 | Used to assess fetal reserve when NST non-reactive. |
| 59050 | Fetal monitoring during labor by consulting physician; with interpretation and report | 000 | Perinatology consult for high-risk labor (severe PE, abruption). |
Gynecologic Surgical Procedures
| CPT Code | Description | Global Period | Notes |
|---|---|---|---|
| 58100 | Endometrial sampling (biopsy) without cervical dilation | 000 | Office procedure for evaluation of abnormal uterine bleeding, postmenopausal bleeding (endometrial cancer screening), AUB. Report with ICD-10 reason for procedure. |
| 58120 | Dilation and curettage (D&C), diagnostic and/or therapeutic | 010 | Used for endometrial sampling, incomplete abortion, molar pregnancy evacuation. May also be coded 59870 for molar pregnancy. |
| 58150 | Total abdominal hysterectomy (TAH), corpus and cervix, with or without removal of tube(s), with or without removal of ovary(s) | 090 | Open abdominal approach. Used for endometrial cancer, cervical cancer, fibroids, leiomyosarcoma. Specify BSO (+58661 or included per code description). |
| 58180 | Supracervical abdominal hysterectomy (subtotal), with or without removal of tube(s), with or without removal of ovary(s) | 090 | Cervix left in place. Less common for malignancy. |
| 58200 | Total abdominal hysterectomy, including partial vaginectomy; with para-aortic and pelvic lymph node sampling, with or without removal of tube(s), with or without removal of ovary(s) | 090 | Radical hysterectomy for cervical/endometrial cancer staging. |
| 58210 | Radical abdominal hysterectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy), with or without removal of tube(s), with or without removal of ovary(s) | 090 | Wertheim procedure for invasive cervical cancer. High-complexity. Requires documentation of cancer diagnosis, stage, and surgical plan. |
| 58260 | Vaginal hysterectomy, for uterus 250 g or less | 090 | Specify uterine weight from operative/pathology report. Affects CPT selection (58260 vs. 58262 vs. 58263). |
| 58262 | Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s) | 090 | |
| 58541 | Laparoscopic, subtotal hysterectomy, uterus 250 g or less | 090 | Laparoscopic approach — must document uterine weight and extent of procedure. FY2026 — verify no change in AMA CPT. |
| 58542 | Laparoscopic, subtotal hysterectomy, uterus 250 g or less; with removal of tube(s) and/or ovary(s) | 090 | |
| 58543 | Laparoscopic, subtotal hysterectomy, uterus greater than 250 g | 090 | |
| 58544 | Laparoscopic, subtotal hysterectomy, uterus greater than 250 g; with removal of tube(s) and/or ovary(s) | 090 | |
| 58550 | Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less (laparoscopic-assisted vaginal hysterectomy) | 090 | LAVH — combined laparoscopic and vaginal approach. |
| 58552 | LAVH with removal of tube(s) and/or ovary(s), uterus 250 g or less | 090 | |
| 58553 | LAVH, uterus greater than 250 g | 090 | |
| 58554 | LAVH with removal of tube(s) and/or ovary(s), uterus greater than 250 g | 090 | |
| 58570 | Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less | 090 | TLH — total laparoscopic hysterectomy. FY2026 standard of care for many benign conditions. |
| 58571 | TLH with removal of tube(s) and/or ovary(s), uterus 250 g or less | 090 | TLH + BSO for BRCA mutation carriers, ovarian/endometrial cancer. |
| 58572 | TLH, uterus greater than 250 g | 090 | |
| 58573 | TLH with removal of tube(s) and/or ovary(s), uterus greater than 250 g | 090 | |
| 58661 | Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy) | 090 | Standalone salpingo-oophorectomy. For BRCA mutation carriers undergoing risk-reducing BSO without hysterectomy. |
| 58900 | Biopsy of ovary, unilateral or bilateral (when performed at time of other major procedure) | 000 | Ovarian biopsy for staging or diagnosis. |
| 58943 | Oophorectomy, partial or total, unilateral; for ovarian, tubal or primary peritoneal malignancy, with para-aortic and pelvic lymph node biopsies, peritoneal washings, peritoneal biopsies, diaphragmatic assessments, with or without salpingectomy, with or without omentectomy | 090 | Comprehensive ovarian cancer staging procedure. |
| 58950 | Resection of ovarian, tubal or primary peritoneal malignancy with bilateral salpingo-oophorectomy and omentectomy | 090 | Ovarian cancer cytoreductive surgery. Must document malignancy and extent. |
| 59320 | Cerclage of cervix, during pregnancy; vaginal | 010 | Cervical cerclage for cervical insufficiency (O34.3x). Shirodkar or McDonald technique. |
| 59325 | Cerclage of cervix, during pregnancy; abdominal | 090 | Abdominal cerclage for cases where vaginal cerclage has failed. |
🧾 HCPCS (2026)
| HCPCS Code | Description | Typical Use in OBGYN |
|---|---|---|
| J1050 | Injection, medroxyprogesterone acetate, 1 mg (Depo-Provera) | Injectable progestin contraception (150 mg = 150 units); also used for endometriosis-related pain, endometrial hyperplasia management, and palliative treatment of endometrial cancer. Administered IM every 3 months. |
| J1725 | Injection, hydroxyprogesterone caproate, 10 mg (17-OHPC / Makena) | 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth in women with singleton pregnancy and prior spontaneous preterm birth. Note: FDA withdrew approval for Makena in 2023 after confirmatory trial failed to show efficacy. Compounded 17-OHPC may still be prescribed and billed; use J1725 for compounded product per payer guidance. Verify payer coverage prior to dispensing. |
| J9035 | Injection, bevacizumab, 10 mg (Avastin) | Used in advanced/recurrent ovarian cancer (often off-label; bevacizumab is FDA-approved for front-line ovarian cancer in combination with carboplatin/paclitaxel). Report per 10 mg unit. |
| J9999 | Not otherwise classified, antineoplastic drugs | Used for PARP inhibitors (olaparib, niraparib, rucaparib) administered in BRCA-mutated ovarian cancer when a specific J code is not available. Verify with individual payer; many have issued specific codes (e.g., J9203 = olaparib). |
| J0897 | Injection, denosumab, 1 mg (Prolia/Xgeva) | Denosumab (Prolia) 60 mg = 60 units, given every 6 months for postmenopausal osteoporosis. Xgeva 120 mg used for bone metastases from solid tumors (e.g., ovarian, breast cancer bone metastases). |
| J3490 | Unclassified drugs | Catch-all for drugs not otherwise classified; may be used for compounded progesterone vaginal preparations, specialty OBGYN medications. Document drug name, dose, and route in claim documentation. |
| S9434 | Modified solid food supplements for inborn errors of metabolism or PKU, per meal | Not applicable to OBGYN directly; included for completeness per specialty coding context. |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Medicare preventive service — annual cervical/vaginal cancer screening physical exam. Used in women who are at high risk or who have had a hysterectomy with removal of cervix. |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | Liquid-based cervical cytology (ThinPrep Pap). Medicare covers cervical cancer screening per established intervals. |
| Q0091 | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Collection service for Pap smear. Typically billed by clinical provider separate from the interpretation code. |
📝 Coder Note
The J1725 (17-OHPC) situation requires careful payer verification. Since FDA’s 2023 withdrawal of Makena, most commercial payers have updated their policies. Some Medicaid plans still cover compounded 17-OHPC under specific state policies. Always verify prior authorization status and current formulary before reporting J1725 on claims. Document the compounded preparation, dose, lot number, and administering provider.
📚 AHA Coding Clinic (Recent Guidance)
The following AHA Coding Clinic advisories are relevant to OBGYN risk-adjusting conditions. Coders should access the current subscription for full text and updates.
| Topic | Coding Clinic Reference / Guidance Summary |
|---|---|
| HELLP Syndrome coding | AHA Coding Clinic has addressed the distinction between severe preeclampsia with HELLP vs. standalone HELLP syndrome, confirming O14.2x is the appropriate code and that HELLP is always a form of severe preeclampsia. Do NOT code O14.1x (severe PE without HELLP) in addition to O14.2x. |
| Gestational diabetes — insulin use | Coding Clinic guidance confirms that if a patient with GDM is using insulin at any point during the encounter, the insulin-controlled code (O24.414 for antepartum) should be reported, even if diet control is also being used. Use Z79.4 (long-term insulin use) as additional code. |
| Placenta previa vs. low-lying placenta | Clarification that “low-lying placenta” documented without hemorrhage is coded to O44.4xx, while true “placenta previa” (reaching or overlapping the os) uses O44.0–O44.3 based on completeness and hemorrhage status. Ultrasound report specificity drives code selection. |
| Osteoporosis with fracture sequencing | AHA Coding Clinic has addressed sequencing when osteoporosis with fracture is the reason for an inpatient admission: M80.xx should be principal diagnosis. If only the fracture is treated without addressing the osteoporosis, the fracture code still drives the M80 category (not a separate S-code) per coding convention. |
| Cancer — primary vs. metastatic (ovarian) | When a patient with ovarian cancer is admitted for a complication of a hepatic metastasis, if the complication drives the admission, C78.7 (secondary malignant neoplasm of liver) may be sequenced first, per Coding Clinic guidance on “treatment directed at the metastatic site.” |
| Ectopic pregnancy — heterotopic | For heterotopic pregnancy (simultaneous ectopic and intrauterine pregnancy), Coding Clinic directs use of the “with intrauterine pregnancy” variant codes (e.g., O00.11 tubal pregnancy with intrauterine pregnancy). Both pregnancies should be fully documented. |
| Cerclage and cervical incompetence | Coding Clinic confirms O34.3x covers both the incompetent cervix itself and the presence of a cerclage. If cerclage removal and replacement occur in the same encounter, report the cerclage removal/placement CPT codes and the O34.3x diagnosis only once. |
💰 HCC / Risk Adjustment (v28)
The following table summarizes HCC mappings under CMS-HCC Model v28 for gynecologic conditions, and the HHS-HCC model for ACA exchange pregnancy conditions.
| ICD-10-CM | Condition | Model | HCC Category | RAF Weight (approx.) | RAF Impact |
|---|---|---|---|---|---|
| C56.1, C56.2, C56.3 | Ovarian cancer (primary, no mets) | CMS-HCC v28 | HCC 22 (Lung and Other Severe Cancers) | ~0.9–1.1 (community, age-adjusted) | HIGH — Significant resource utilization for surgery, chemo, surveillance |
| C56.x + C78.x | Ovarian cancer with metastases | CMS-HCC v28 | HCC 17 (Metastatic Cancer and Acute Leukemia) | ~2.4–2.7 (community, age-adjusted) | VERY HIGH — Metastatic category carries much higher weight than HCC 22 |
| C53.x | Cervical cancer | CMS-HCC v28 | HCC 22 | ~0.9–1.1 | HIGH |
| C54.x, C55 | Endometrial/uterine cancer | CMS-HCC v28 | HCC 22 | ~0.9–1.1 | HIGH |
| C50.x (female) | Breast cancer | CMS-HCC v28 | HCC 22 | ~0.9–1.1 | HIGH — Must confirm active malignancy vs. history (Z85.3) |
| M80.0xxA, M80.05xA | Osteoporosis with pathological fracture (any site; hip/femur) | CMS-HCC v28 | HCC 170 / 171 | ~0.3–0.5 | MODERATE — Hip fracture has highest weight within this category |
| O14.1x, O14.2x, O15.xx | Severe preeclampsia / HELLP / Eclampsia | HHS-HCC (Adult Female) | HHS-HCC Pregnancy Complication hierarchy | Varies by plan year; ACA transfer formula | HIGH — Pregnancy complications are among the highest HHS-HCC triggers for ACA plans |
| O00.xx, O01.xx | Ectopic / molar pregnancy | HHS-HCC | HHS-HCC Ectopic/Molar Pregnancy | ACA transfer formula | HIGH |
| O22.3x–O22.5x | Pregnancy-related VTE (DVT/CVT) | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH — DVT in pregnancy significantly increases expected costs |
| O24.41x | Gestational diabetes (insulin-controlled) | HHS-HCC | HHS-HCC Pregnancy Complication (may apply) | ACA transfer formula | MODERATE — Insulin-controlled GDM has greater weight than diet-controlled |
| O45.xx | Abruptio placentae | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH |
| O44.xx | Placenta previa | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH |
| O46.xx | Antepartum hemorrhage | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH |
| O30.xx | Multiple gestation | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH — Multiple gestation significantly increases expected expenditures |
| O34.3x | Cervical insufficiency | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | MODERATE |
| O60.xx | Preterm labor | HHS-HCC | HHS-HCC Pregnancy Complication | ACA transfer formula | HIGH — Preterm delivery is a major cost driver for neonatal ICU care |
| Z15.01, Z15.02 | BRCA genetic susceptibility | Neither | No HCC mapping | 0.0 | NONE — Z codes do not risk-adjust; underlying malignancy codes do |
| N80.x, N81.x, N94.x, D25.x, N95.x | Endometriosis, prolapse, pelvic pain, fibroids, menopause | Neither | No HCC mapping | 0.0 | NONE |
⚠️ Common Pitfall
HCC 17 vs. HCC 22: The distinction between metastatic and non-metastatic gynecologic cancer has a profound RAF impact. Ovarian cancer with peritoneal spread codes to HCC 17 (weight ~2.4–2.7) vs. HCC 22 for localized disease (~0.9–1.1). Coders must capture all metastatic sites documented in pathology reports, operative notes, and imaging reports. Do NOT assume all ovarian cancer is HCC 22 without reviewing current staging documentation.
💬 CDI Query Trigger
For a Medicare Advantage patient with ovarian cancer whose CT scan reports “peritoneal implants consistent with metastatic disease” but the attending’s note documents only “ovarian carcinoma, FIGO Stage III,” clarify with the oncologist: Are peritoneal implants representing metastatic spread from the ovarian primary? If so, should the diagnosis of secondary malignant neoplasm of the peritoneum (C78.6) be documented in addition to the ovarian cancer? This distinction drives the difference between HCC 22 and HCC 17.
✍️ CDI Query Templates
All queries below comply with ACDIS and AHIMA compliant physician query guidelines — non-leading, multiple-choice format.
| Clinical Scenario | Query Wording |
|---|---|
| Patient with hypertension in pregnancy and proteinuria; note says “hypertensive disorder of pregnancy” — no severity specified | The clinical record documents elevated blood pressures (highest ___/___), new-onset proteinuria (___), and the following symptoms: [headache / visual changes / RUQ pain / thrombocytopenia / elevated liver enzymes — circle all that apply]. Based on your clinical assessment, does the patient’s condition most accurately represent: (A) Gestational hypertension without proteinuria; (B) Preeclampsia without severe features; (C) Severe preeclampsia; (D) HELLP syndrome; (E) Eclampsia; or (F) Other — please specify. Your response will support accurate clinical documentation and coding. |
| GDM patient receiving insulin injections; note documents “gestational diabetes, managed” | The record indicates a diagnosis of gestational diabetes mellitus with insulin administered during this encounter/pregnancy. To support accurate clinical documentation, how is the patient’s gestational diabetes being managed? (A) Diet and exercise only; (B) Oral hypoglycemic medication (specify: ___); (C) Insulin; (D) Combination diet and oral medication; (E) Other — specify. Please document the management modality in your note. |
| Patient with ovarian cancer — imaging shows hepatic lesions described as “liver lesions, metastatic vs. benign” | The patient has a known diagnosis of ovarian carcinoma. Recent imaging ([date]) documents liver lesion(s) described as [quote from radiology report]. Based on your clinical assessment and available diagnostic results, do these hepatic lesions most accurately represent: (A) Secondary/metastatic malignant neoplasm of the liver from the ovarian primary; (B) Benign hepatic lesion(s) unrelated to the ovarian cancer; (C) Indeterminate — further workup required; or (D) Other — please specify. This information is needed for complete clinical documentation. |
| Postmenopausal patient with vertebral fracture; radiology reads “T12 compression fracture, likely osteoporotic” — no physician documentation of osteoporosis | Radiology documents a compression fracture at T12 described as “likely osteoporotic.” The patient is a [age]-year-old postmenopausal female. To ensure complete documentation, can you confirm whether: (A) This fracture is due to age-related (postmenopausal) osteoporosis with pathological fracture; (B) This is a traumatic fracture (not due to osteoporosis); (C) Other metabolic bone disease is responsible (please specify); or (D) The etiology is undetermined at this time. If osteoporosis is present, please document in the medical record. |
| Pregnant patient with positive DVT ultrasound; documentation reads “thrombosis in pregnancy” without site specificity | The duplex ultrasound dated [___] confirmed thrombosis in the [right/left] [___] vein. For accurate clinical documentation and to ensure appropriate anticoagulation therapy documentation, does the patient have: (A) Superficial thrombophlebitis of the [___] leg in pregnancy; (B) Deep vein thrombosis of the [___] leg in pregnancy (specify femoral / popliteal / calf); (C) Pelvic vein thrombosis in pregnancy; (D) Cerebral venous thrombosis in pregnancy; or (E) Other — please specify site and depth. Document trimester at time of diagnosis. |
| BRCA mutation patient with bilateral prophylactic salpingo-oophorectomy — no current cancer documented | The patient underwent bilateral salpingo-oophorectomy (RRSO). Pathology report result: [___]. In the absence of confirmed malignancy, does the patient carry a documented BRCA1 or BRCA2 mutation conferring genetic susceptibility to cancer? If so, please document the genetic susceptibility and type (BRCA1 or BRCA2) in the medical record to support preventive service coding and patient care continuity. |
🧑⚕️ Treatments (Clinical)
Obstetric Complications — Evidence-Based Management
- Severe preeclampsia: Definitive treatment is delivery. For gestational ages ≥37 weeks, immediate delivery is recommended (ACOG Practice Bulletin 222). For preterm severe PE, expectant management may be considered at 34–36 weeks in select cases. Maternal stabilization: IV labetalol, IV hydralazine, or PO nifedipine for acute severe hypertension; IV magnesium sulfate for seizure prophylaxis.
- HELLP syndrome: Delivery is the only cure. Platelet transfusion for platelets <50,000/µL before procedure. Corticosteroids may temporarily improve platelet count. ICU-level care often required.
- Gestational diabetes: MNT first-line (carbohydrate-controlled diet per ACOG guidance); insulin added if glucose targets not met within 1–2 weeks; postpartum 75g OGTT at 6–12 weeks to screen for persistent type 2 DM.
- Abruptio placentae: Emergency C/S for non-reassuring fetal status or severe hemorrhage; vaginal delivery possible in stable cases with favorable cervix; massive transfusion protocol for DIC; neonatal resuscitation team on standby.
- Placenta previa: Scheduled C/S at 36–37 weeks for stable complete previa per ACOG guidelines; pelvic rest, no digital cervical exams; hospital admission for active bleeding; crossmatch blood products.
- Pregnancy-related VTE: LMWH (enoxaparin weight-based dosing) throughout pregnancy and ≥6 weeks postpartum; anti-Xa monitoring for obese patients, renal impairment, or extremes of weight; IVC filter reserved for contraindication to anticoagulation.
- Cervical insufficiency: Cervical cerclage (McDonald or Shirodkar technique) for history-indicated or ultrasound-indicated indications at 12–24 weeks; vaginal progesterone for short cervix (<25mm) in singletons; removal at 36–37 weeks.
Gynecologic Malignancies — Multidisciplinary Management
- Ovarian cancer: Primary cytoreductive surgery (TAH/BSO + omentectomy + pelvic/para-aortic lymphadenectomy + peritoneal biopsies) followed by platinum/taxane chemotherapy. PARP inhibitor maintenance (olaparib, niraparib) for BRCA-mutated or HRD-positive disease. NACT (neoadjuvant chemotherapy) + interval debulking for patients who cannot tolerate primary surgery. NCCN Ovarian Cancer guidelines.
- Cervical cancer: Early-stage (IA–IIA): radical hysterectomy + pelvic LND or chemoradiation. Locally advanced (IIB–IVA): concurrent cisplatin + external beam radiation + brachytherapy. Metastatic: pembrolizumab + chemotherapy for PD-L1+ disease (NCCN Cervical Cancer).
- Endometrial cancer: TH/BSO ± sentinel lymph node mapping for early-stage; adjuvant radiation or chemotherapy based on risk factors; carboplatin + paclitaxel for advanced/recurrent; pembrolizumab + lenvatinib for TMB-high or MSI-H/dMMR tumors (NCCN Uterine Neoplasms).
- Osteoporosis with fracture: Orthopedic management of fracture (hip arthroplasty, vertebroplasty/kyphoplasty for vertebral fractures, ORIF as indicated); pharmacological anti-resorptive therapy (oral bisphosphonates, IV zoledronic acid 5 mg annually, denosumab 60 mg SC every 6 months); teriparatide/abaloparatide for high-risk patients; fall prevention (PT, home safety evaluation, calcium + vitamin D).
🎓 Patient Education / Summary
For Pregnant Patients with High-Risk Conditions
If you have been diagnosed with a high-risk pregnancy condition, here is what you should know:
- Preeclampsia/severe preeclampsia: This is a serious blood pressure condition that can only be cured by delivering the baby. Warning signs that require immediate medical attention include severe headache, vision changes (spots, blurring), pain in the upper right abdomen, sudden swelling of the face or hands, or decreased fetal movement. Contact your provider or go to labor and delivery immediately if you experience these symptoms. Your plan of care — including when to deliver — will be made by your care team based on how serious your condition is and how far along you are in your pregnancy. Learn more at Preeclampsia Foundation.
- Gestational diabetes: GDM means your body is not managing blood sugar well during pregnancy. You can help control it by following your prescribed diet, checking your blood sugar as instructed, taking medication if prescribed (insulin or pills), and attending all follow-up visits. Most women’s blood sugar returns to normal after delivery, but GDM increases your long-term risk of type 2 diabetes. Get tested at your 6-week postpartum visit. Learn more at American Diabetes Association — Gestational Diabetes.
- Blood clots (DVT/PE) in pregnancy: If you are on blood thinners (heparin or enoxaparin/Lovenox injections), do not stop them without talking to your doctor. Report any new leg swelling, pain, shortness of breath, or chest pain right away. Blood thinners used in pregnancy are safe for your baby and necessary to protect your health.
- Placenta previa / placental abruption: You will likely need to deliver by cesarean section. Follow all activity restrictions (pelvic rest, no intercourse, avoid strenuous activity). Go to the hospital immediately for any vaginal bleeding. Keep hospital bag ready and know the fastest route to your delivery hospital.
For Women with Gynecologic Cancer or at High Risk
- Ovarian, cervical, or uterine cancer: Your care team includes gynecologic oncologists, medical oncologists, and radiation oncologists who will work together on your treatment plan. Do not miss scheduled appointments — early and consistent treatment gives the best outcomes. Bring a trusted person to appointments to help remember information. Society of Gynecologic Oncology patient resources are available online.
- BRCA mutation: A BRCA1 or BRCA2 mutation means you have a higher lifetime risk of developing breast and ovarian cancer. This does not mean you have cancer now. Talk to your provider about risk-reducing options, including enhanced screening (MRI + mammogram annually), risk-reducing medications (chemoprevention), or preventive surgery (bilateral mastectomy, salpingo-oophorectomy). Genetic counseling can help you and your family understand what this means. FORCE: Facing Our Risk of Cancer Empowered provides patient support and resources.
- Osteoporosis with fracture: Taking your osteoporosis medication as prescribed is important — many medications must be taken for years to reduce fracture risk. Take calcium (total 1,200 mg/day from food + supplements) and vitamin D (800–1,000 IU/day). Practice fall prevention at home: remove trip hazards, install grab bars in the bathroom, wear non-slip shoes. Talk to your doctor before stopping any osteoporosis medication. National Osteoporosis Foundation provides patient education.
💬 CDI Query Trigger
When a postmenopausal patient is discharged after hip replacement following a fall at home with no significant trauma, query the orthopedic or admitting physician: Was this hip fracture a pathological/fragility fracture due to underlying osteoporosis, or was it the result of a traumatic mechanism of injury? If osteoporosis is the underlying cause, this should be documented clearly in the discharge summary to support the M80.05xA code (osteoporosis with pathological fracture, femur) and enable appropriate HCC v28 capture (HCC 170).
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
